Marye J Gleva1, Melissa Robinson2, Jeanne Poole3. 1. Washington University in St. Louis, St. Louis, MO, USA. 2. University of Washington, 1959 NE Pacific Street, Box 356422, Seattle, WA, 98195, USA. 3. University of Washington, 1959 NE Pacific Street, Box 356422, Seattle, WA, 98195, USA. JPoole@cardiology.washington.edu.
Abstract
PURPOSE OF REVIEW: In the current era of implantable cardioverter-defibrillator procedures, the decision of whether or not to perform defibrillation threshold testing at the time of implantation is now less of a clinical conundrum. In this paper, we summarize this current practice, beginning with the physiology of defibrillation, followed by a review of the salient data, and discussion of specific situations where defibrillation threshold testing remains a clinical consideration. RECENT FINDINGS: Two prospective randomized trials demonstrated no mortality difference and no overall complication rate difference between patients who underwent defibrillation testing at implant compared with patients who underwent no defibrillation testing. Current recommendations support eliminating routine defibrillation testing in left-sided transvenous implantable cardioverter-defibrillator primary prevention implants. Defibrillation testing remains indicated in subcutaneous defibrillator implants in the absence of contraindications.
PURPOSE OF REVIEW: In the current era of implantable cardioverter-defibrillator procedures, the decision of whether or not to perform defibrillation threshold testing at the time of implantation is now less of a clinical conundrum. In this paper, we summarize this current practice, beginning with the physiology of defibrillation, followed by a review of the salient data, and discussion of specific situations where defibrillation threshold testing remains a clinical consideration. RECENT FINDINGS: Two prospective randomized trials demonstrated no mortality difference and no overall complication rate difference between patients who underwent defibrillation testing at implant compared with patients who underwent no defibrillation testing. Current recommendations support eliminating routine defibrillation testing in left-sided transvenous implantable cardioverter-defibrillator primary prevention implants. Defibrillation testing remains indicated in subcutaneous defibrillator implants in the absence of contraindications.
Authors: Stefan H Hohnloser; Paul Dorian; Robin Roberts; Michael Gent; Carsten W Israel; Eric Fain; Jean Champagne; Stuart J Connolly Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: T Tokano; F Pelosi; M Flemming; L Horwood; J J Souza; A Zivin; B P Knight; R Goyal; K C Man; F Morady; S A Strickberger Journal: J Cardiovasc Electrophysiol Date: 1998-09
Authors: Andrea M Russo; William Sauer; Edward P Gerstenfeld; Henry H Hsia; David Lin; Joshua M Cooper; Sanjay Dixit; Ralph J Verdino; Hemal M Nayak; David J Callans; Vickas Patel; Francis E Marchlinski Journal: Heart Rhythm Date: 2005-05 Impact factor: 6.343
Authors: Matthew Bennett; Ratika Parkash; Pablo Nery; Mario Sénéchal; Blandine Mondesert; David Birnie; Laurence D Sterns; Claus Rinne; Derek Exner; François Philippon; Debra Campbell; Jafna Cox; Paul Dorian; Vidal Essebag; Andrew Krahn; Jaimie Manlucu; Franck Molin; Michael Slawnych; Mario Talajic Journal: Can J Cardiol Date: 2016-10-06 Impact factor: 5.223
Authors: Jeff S Healey; Stefan H Hohnloser; Michael Glikson; Jorg Neuzner; Phillipe Mabo; Xavier Vinolas; Josef Kautzner; Gilles O'Hara; Lieselot VanErven; Fredrik Gadler; Janice Pogue; Ursula Appl; Jim Gilkerson; Thierry Pochet; Kenneth M Stein; Bela Merkely; Susan Chrolavicius; Brandi Meeks; Csaba Foldesi; Bernard Thibault; Stuart J Connolly Journal: Lancet Date: 2015-02-23 Impact factor: 79.321
Authors: Mina K Chung; Richard G Holcomb; Suneet Mittal; Jonathan S Steinberg; Marye J Gleva; Theofanie Mela; Daniel Z Uslan; Kevin Mitchell; Jeanne E Poole Journal: Circ Arrhythm Electrophysiol Date: 2014-09-14